The article discusses the role of gut microbiota in patients with inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC). It highlights the importance of gut microbiota in the pathogenesis of IBD, emphasizing that dysbiosis in the gut microbiota may increase the risk of developing IBD. The study reviews scientific studies, particularly systematic reviews and meta-analyses, regarding the microbiota of IBD patients compared to healthy individuals and the use of various probiotic strains in IBD therapy. The research indicates that factors such as genetic, immunological, and lifestyle factors contribute to the development of IBD, and that the gut microbiota plays a crucial role in immune response modulation. The study also explores the impact of probiotic strains on the gut microbiota and health, showing that certain strains, such as Saccharomyces boulardii, Lactic Acid Bacteria, and Escherichia coli strain Nissle 1917, have beneficial effects in the treatment of IBD. The study further discusses the use of prebiotics and synbiotics in IBD treatment, showing that they can support the maintenance of remission. The research concludes that probiotic therapy, particularly multi-strain formulations, may be effective in the treatment of IBD, with the best results observed when used in combination with standard pharmacotherapy. The study also notes that the use of probiotics is generally safe, with minimal side effects, and that further research is needed to identify the most effective strains for IBD treatment.The article discusses the role of gut microbiota in patients with inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC). It highlights the importance of gut microbiota in the pathogenesis of IBD, emphasizing that dysbiosis in the gut microbiota may increase the risk of developing IBD. The study reviews scientific studies, particularly systematic reviews and meta-analyses, regarding the microbiota of IBD patients compared to healthy individuals and the use of various probiotic strains in IBD therapy. The research indicates that factors such as genetic, immunological, and lifestyle factors contribute to the development of IBD, and that the gut microbiota plays a crucial role in immune response modulation. The study also explores the impact of probiotic strains on the gut microbiota and health, showing that certain strains, such as Saccharomyces boulardii, Lactic Acid Bacteria, and Escherichia coli strain Nissle 1917, have beneficial effects in the treatment of IBD. The study further discusses the use of prebiotics and synbiotics in IBD treatment, showing that they can support the maintenance of remission. The research concludes that probiotic therapy, particularly multi-strain formulations, may be effective in the treatment of IBD, with the best results observed when used in combination with standard pharmacotherapy. The study also notes that the use of probiotics is generally safe, with minimal side effects, and that further research is needed to identify the most effective strains for IBD treatment.